Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized EGCG for COVID-19 Pneumonia in Cancer Patients
NCT06924749Phase 2Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epigallocatechin gallate in COVID-19 pneumonia (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: CT imaging improvement rate of COVID-19 at 7 days. Started Jun 2023; status: completed.
02
Drugs
epigallocatechin gallate
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT06924749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924749.